This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.

Mobile version  RSS  Subscribe  Unsubscribe  Archive  Media Kit |   AhHa B2B Search:     

Home   About AST   Education   Meetings & Events   Public Policy   Contact Us   Oct. 25, 2012



AST's Cutting Edge of Transplantation Abstract Deadline is Oct. 31
AST    Share   Share on FacebookTwitterShare on LinkedinE-mail article
Why you should submit an abstract to CEOT...
B cells have re-emerged as a major player in clinical organ transplantation as well as autoimmune disease. Antibodies (Ab) are being increasingly recognized as a participant in rejection. But Ab detection techniques are now very sensitive, and may detect Abs that are not clinically relevant. Thus, questions remain on how to best diagnose and who to treat. With the advent of B cell-directed rather than just Ab-directed therapies, the best approach for treatment is also unclear.

View the full program on the AST CEOT website.

A key aspect of this meeting is that it brings together basic scientists, translational scientists and clinical scientists who all have their own perspectives. Allowing each to focus on the same problems in an interactive forum will allow basic scientists to identify clinically relevant questions required to improve therapy and provide clinical scientists with new targets to translate for clinical development.

See the list of expert faculty.

Iso-Tex Diagnostics, Inc.

• We are an FDA licensed manufacturer.
• We label peptides, monoclonal antibodies, reagents, chemical   and proteins for cancer treatments.
• Our above products can be labeled with radioisotopes such as   I-125, I-131, P32, Tc99m, Y90 and AC-225.
• We have a multicurie isotope license and an animal facility.

2013 dues invoice
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
2012 proved to be an extremely exciting year for the AST. AST initiatives and successes touched all aspects of our field demonstrating why the AST is transplantation's most highly regarded and influential society.

With the end of the year quickly approaching, members are encouraged to renew their membership now. 2013 dues invoices were recently mailed and your continued commitment to the AST is critical to the ongoing success of our society. Renewing your membership is easy. Go to the AST website to renew online or complete the dues invoice and return to the AST office. If renewing online, simply log-in and click on Renew My Membership. A confirmation email will be sent to you once your payment is processed.

C1qScreen™: A New Research Tool for AMR Risk
Identify Antibodies That May Compromise Graft Survival
  • Detect Presence of Complement Fixing Antibodies
  • Investigate risk of developing Antibody Mediated Rejection (AMR)
Request a Complimentary Sample Kit!

For Research Use Only. Not for use in diagnostic procedures.

Do you know about AST's new Institutional Support Program?
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Are you interested in receiving recognition and increased exposure for your transplant center? Do you support the future of transplantation and value the educational, networking and research opportunities that the American Society of Transplantation (AST) provides to its members? If the answer to these questions is yes, please consider having your center participate in AST's Institutional Support Program.

With a charitable contribution of $3,000, your center will receive valuable benefits, including recognition through the year and access to the AST membership. For more information or to make a contribution, click here. All donations are tax-deductible.

ATC 2012 highlights: Free on demand webcasts
AST    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Education when you want it, in less than 60 minutes! Now added to the Timely Topics in Transplantation on demand webcast series: ATC 2012 highlights in infectious disease, live donation and thoracic transplantation. These webcasts are free to AST members and can be viewed any time, at your leisure. Non-members may view the webcasts for only $25 each.

Coming soon: ATC 2012 highlights in multi-organ transplantation.

Athena Diagnostics

Genetic testing can be a cost-effective way to increase the number of living related donor transplants. Mutational analysis may help direct long-term treatment plans, including pre-operative screening of potential kidney transplant recipients and living related donors.
WAVES by Waters Medical Systems
✓ Hypothermic preservation of a single kidney using physiologic pulsatile preservation and membrane oxygenation: a proven technology from Waters Medical Systems (more than 40 years clinical experience) ✓ Simplifies the perfusion process (provides more options to view, chart, and trend data, offers web-based remote monitoring, and a transportable design)
✓ Meets or exceeds current FDA standards and AOPO and UNOS Preservation Guidelines.
MNX: Organ Transportation
When it comes to saving lives, MNX understands organ transplant logistics. Every shipment is urgent, and every step critical. That’s why MNX offers specialty services that are tailored for organ transportation. From expedited ground service to charter flights, MNX has the proven experience and operational resources you can count on.


Specific aspects of children and adolescents undergoing lung transplantation
Current Opinion in Organ Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Lung transplantation has successfully been performed in infants, children and adolescents with outcomes similar to that in adults. Specific aspects of paediatric lung transplantation include donor shortage for smaller recipients, somatic growth, psychosocial aspects and adherence, and transition to adult care. More

Preclinical efficacy and immunological safety of fr104, an antagonist anti-cd28 monovalent fab' antibody
American Journal of Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Antagonist anti-CD28 antibodies prevent T cell costimulation and differentiate from CTLA4Ig since they cannot block CTLA-4 and PDL-1 coinhibitory signals. They demonstrated efficacy in suppressing effector T cells while enhancing regulatory T cells function and immune tolerance. However, anti-CD28 antibodies devoid of immunotoxicity and with a good pharmacokinetic profile have not yet been developed. FR104, a novel humanized pegylated anti-CD28 Fab′ antibody fragment presenting a long elimination half-life in monkeys is described in the following article. More

BK virus viremia in a well-HLA-matched kidney transplant population mainly on low-dose cyclosporine-based immunosuppression
Clinical Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The incidence and clinical course of polyomavirus-associated nephropathy (PyVAN) in a well-HLA-matched kidney transplant population mainly on low-dose cyclosporine-based triple-drug immunosuppression has not been described in detail. Researchers aimed to characterize patients with PyVAN and BK virus (BKV) viremia. Even in a low-risk population, BKV viremia and PyVAN occur, highlighting the importance of monitoring viral loads. Reduction of immunosuppression was successful, and no grafts were lost due to PyVAN. More

Mini-incision right hepatic lobectomy with or without laparoscopic assistance for living donor hepatectomy
Liver Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Minimally invasive procedures are considered to be safe and effective approaches to the management of surgical liver disease. However, this indication remains controversial for living donor hepatectomy. Minimally invasive LDRH can be performed without safety being impaired. LDRH with a 10-cm upper midline incision and without laparoscopic assistance may be appropriate for donors with a smaller body mass. Laparoscopic assistance can be added as needed for larger donors. More

Prevention and treatment of coronary artery vasculopathy
Current Opinion in Organ Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Cardiac allograft vasculopathy (CAV) is still one of the major causes of death following heart transplantation. Here, resarchers review the recent advances in its prevention and treatment. The implementation of measures and lifestyles that help prevent CAV should be a priority of postheart transplantation management. Research should urgently evaluate mTOR inhibitors for the treatment of established CAV. More

Preoperative prediction of the microvascular invasion of hepatocellular carcinoma with diffusion-weighted imaging
Liver Transplantation (subscription required)    Share    Share on FacebookTwitterShare on LinkedinE-mail article
The aim of a recent study was to investigate whether diffusion-weighted imaging (DWI) could be useful in predicting the microvascular invasion (MVI) of hepatocellular carcinoma (HCC). Sixty-seven surgically proven HCCs from 65 patients (54 men and 11 women with an age range of 35-75 years and a mean age of 56.0 years) were retrospectively analyzed. A univariate analysis showed that a histological grade of three, a larger tumor size, a higher SI ratio on DW images and a lower ADC value were significantly associated with MVI. More

Infection-related hospitalizations common post-transplant
Renal & Urology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Most renal transplant recipients require at least one hospitalization after transplantation surgery, and infections are among the most common reasons, new findings suggest. Most of these hospitalizations occur within six months after transplantation, indicating the need for close follow-up during this time period, said lead investigator Dr. Elena Beam, an internal medicine resident at Mayo Clinic in Rochester, Minn. "We found in the first year after transplantation that a majority of patients ended up getting hospitalized and the usual stay was three days," Dr. Beam said. "This is something that increases cost of care." More

AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Courtney Hodges, Content Editor, 972.402.2604   
Contribute news

This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Oct. 18, 2012
Oct. 11, 2012
Oct. 5, 2012
Sept. 27, 2012

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063